Schizophrenia

June, 2011 | Vol: 9 Issue: 6

In this issue

Learning Objective

Article

Latuda: “Procognitive” or Pro-Profit? [Subscribers Only]

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

Cognitive Deficits in Schizophrenia

In what ways, if any, are cognitive problem a distinct feature of schizophrenia? And how can we use this information to guide treatment?

2011 Atypical Antipscyhotics Table

Check out this table for details on all of the atypical antipsychotics you commonly prescribe.

Information in this table is on the June CME Test, so please read it with the rest of this issue's content.

Expert QA

Attenuated Psychosis Syndrome

Dr. Carpenter, you are a member of the DSM-5 work group that is considering risk syndrome for first psychosis, or what is now called “attenuated psychosis syndrome” as a new diagnosis in the manual.

Research Update

“Soft” Bipolar Does Not Affect Antidepressant Treatment Outcomes

A combination of clinical lore and some studies have led many psychiatrists to believe that it is crucial to screen depressed patients for subtle signs of “bipolarity.”